These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines. Steel R; Buchak L; Eyal N J Med Ethics; 2020 Dec; 46(12):808-812. PubMed ID: 32661074 [TBL] [Abstract][Full Text] [Related]
4. Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies. Steuwer B; Jamrozik E; Eyal N Int J Infect Dis; 2021 Apr; 105():307-311. PubMed ID: 33592338 [TBL] [Abstract][Full Text] [Related]
5. The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants. Rohrig A; Eyal N J Infect Dis; 2022 Mar; 225(6):934-937. PubMed ID: 34624095 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials. Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768 [TBL] [Abstract][Full Text] [Related]
7. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism. Amanpour S Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
9. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates. Behr MA; Divangahi M; Schurr E J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239 [TBL] [Abstract][Full Text] [Related]
10. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Russell RL; Pelka P; Mark BL Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067 [TBL] [Abstract][Full Text] [Related]
11. Broad cross-national public support for accelerated COVID-19 vaccine trial designs. Broockman D; Kalla J; Guerrero A; Budolfson M; Eyal N; Jewell NP; Magalhaes M; Sekhon JS Vaccine; 2021 Jan; 39(2):309-316. PubMed ID: 33334616 [TBL] [Abstract][Full Text] [Related]
12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
13. Intranasal COVID-19 vaccines: From bench to bed. Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851 [TBL] [Abstract][Full Text] [Related]
14. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related]
16. Learning from the past: development of safe and effective COVID-19 vaccines. Su S; Du L; Jiang S Nat Rev Microbiol; 2021 Mar; 19(3):211-219. PubMed ID: 33067570 [TBL] [Abstract][Full Text] [Related]
17. Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants. Su S; Shao Y; Jiang S Emerg Microbes Infect; 2021 Dec; 10(1):439-441. PubMed ID: 33635184 [No Abstract] [Full Text] [Related]
20. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang H; Wang W; Zhang W; Li N; Xie Z; Ding L; You W; Zhao Y; Yang X; Liu Y; Wang Q; Huang L; Yang Y; Xu G; Luo B; Wang W; Liu P; Guo W; Yang X Lancet Infect Dis; 2021 Jan; 21(1):39-51. PubMed ID: 33069281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]